Typical challenges addressed include insufficient transfection efficiency and unstable expression, unwanted bacterial sequences affecting safety and consistency, limitations of plasmid DNA in virus-free gene modification, and quality issues such as retro-packaging in AAV production or instability of ITR and poly(A) sequences. These challenges directly impact yields, reproducibility, regulatory acceptance, and overall timelines. Minicircle DNA and related technologies address these issues by enabling cleaner vectors, higher functional performance, improved safety profiles, and better suitability for clinical applications.
The webinar presents PlasmidFactory’s end-to-end approach, combining Minicircle DNA with proprietary technologies such as ITRRESCUE®, ITRPROTECT®, and POLYARESCUE®, supported by an integrated GMP manufacturing system. Through close scientific collaboration and long-term partnership, PlasmidFactory helps customers make DNA supply the most stable and lowest-risk element of their development programs.
Learning Objectives
After this webinar, participants will be able to:
- Understand how DNA quality directly affects performance, safety, and scalability
- Recognize how Minicircle-based solutions address common development challenges
- Evaluate how an end-to-end DNA partner can support programs from research to GMP
